MX2016010436A - Compuestos de pirazolona y usos de los mismos. - Google Patents

Compuestos de pirazolona y usos de los mismos.

Info

Publication number
MX2016010436A
MX2016010436A MX2016010436A MX2016010436A MX2016010436A MX 2016010436 A MX2016010436 A MX 2016010436A MX 2016010436 A MX2016010436 A MX 2016010436A MX 2016010436 A MX2016010436 A MX 2016010436A MX 2016010436 A MX2016010436 A MX 2016010436A
Authority
MX
Mexico
Prior art keywords
melanoma
pancreatic
cancers
colon
breast
Prior art date
Application number
MX2016010436A
Other languages
English (en)
Inventor
Simon Stock Nicholas
Mostofi Bravo Yalda
Chih- Yu Chen Austin
Duarte Jacintho Jason
TRUONG Yen
Original Assignee
Inception 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53800550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016010436(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inception 2 Inc filed Critical Inception 2 Inc
Publication of MX2016010436A publication Critical patent/MX2016010436A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención descrita en la presente se refiere a compuestos de la Fórmula I (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, que son útiles en el tratamiento cáncer de próstata, mama, colon, pancreático, leucemia linfocítica crónica humana, leucemia mieloide crónica o aguda, melanoma, y otros cánceres. La invención también incluye composiciones farmacéuticas que comprenden una cantidad terapéuticamente efectiva del compuesto de la Fórmula I, o una sal farmacéuticamente aceptable del mismo. La invención descrita en la presente también se refiere a métodos de tratamiento de cáncer de próstata, mama, ovario, hígado, riñón, colon, pancreático, leucemia linfocítica crónica humana, leucemia mieloide crónica o aguda, melanoma y otros cánceres. La invención descrita en la presente se refiere adicionalmente a métodos de tratamiento de cáncer de próstata, mama, ovario, hígado, riñón, colon, pancreático, leucemia linfocítica crónica humana, leucemia mieloide crónica o aguda, melanoma y otros cánceres a través de la administración de una cantidad terapéuticamente efectiva de un antagonista de PPARa selectivo. Los compuestos y composiciones farmacéuticas de la invención también son útiles en el tratamiento de infecciones virales, tal como infecciones de VHC e infecciones de VIH.
MX2016010436A 2014-02-14 2015-02-09 Compuestos de pirazolona y usos de los mismos. MX2016010436A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939955P 2014-02-14 2014-02-14
PCT/US2015/015000 WO2015123133A1 (en) 2014-02-14 2015-02-09 Pyrazolone compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2016010436A true MX2016010436A (es) 2016-10-31

Family

ID=53800550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010436A MX2016010436A (es) 2014-02-14 2015-02-09 Compuestos de pirazolona y usos de los mismos.

Country Status (16)

Country Link
US (2) US9862708B2 (es)
EP (1) EP3105205A4 (es)
JP (1) JP2017505804A (es)
KR (1) KR20160115996A (es)
CN (1) CN106029640B (es)
AU (1) AU2015217450A1 (es)
BR (1) BR112016017781A2 (es)
CA (1) CA2937542A1 (es)
EA (1) EA201691342A1 (es)
IL (1) IL247148A0 (es)
MX (1) MX2016010436A (es)
NZ (1) NZ722345A (es)
PE (1) PE20161315A1 (es)
SG (1) SG11201606149YA (es)
WO (1) WO2015123133A1 (es)
ZA (1) ZA201605222B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128377A1 (en) * 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
US20230151025A1 (en) 2020-04-07 2023-05-18 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
WO2022194843A1 (en) 2021-03-19 2022-09-22 Bayer Aktiengesellschaft Substituted 1,2,4-thiadiazoles, salts thereof and their use as herbicidally active substances
BR112023022201A2 (pt) 2021-04-27 2023-12-26 Bayer Ag Piridazinonas substituídas, sais ou n-óxidos dos mesmos e seus usos como substâncias herbicidamente ativas
AU2022330302A1 (en) 2021-08-17 2024-02-22 Bayer Aktiengesellschaft Substituted 1,2,4-thiadiazolyl nicotinamides, salts or n-oxides thereof and their use as herbicidally active substances
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
AR127618A1 (es) 2021-11-29 2024-02-14 Bayer Ag Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas
EP4238973A1 (en) 2022-03-04 2023-09-06 Bayer AG Substituted 1,2,4-thiadiazolyl isonicotinamides, salts or n-oxides thereof and their use as herbicidally active substances
EP4238972A1 (en) 2022-03-04 2023-09-06 Bayer AG Substituted 1,2,4-thiadiazolyl picolinamides, salts or n-oxides thereof and their use as herbicidally active substances

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244593A (en) 1963-06-12 1966-04-05 Endo Lab Pharmaceutically active substituted 5-pyrazolones
US4719175A (en) 1982-05-03 1988-01-12 Polaroid Corporation Novel pyrazole compounds having silver halide development groups
DE3312581A1 (de) * 1983-04-08 1984-10-11 Bayer Ag, 5090 Leverkusen Verwendung von pyrazolonderivaten bei der bekaempfung des wachstums von tumorzellen und der metastasenbildung, arzneimittel hierfuer und verfahren zu deren herstellung
JPH02229168A (ja) 1989-03-01 1990-09-11 Takeda Chem Ind Ltd ピラゾロン誘導体
EP0491218A1 (en) * 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US5484940A (en) 1994-11-28 1996-01-16 Grant; Francine S. Substituted 3-indolyl-5-pyrazolone compounds
DE19518082A1 (de) 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
SK1512002A3 (en) 1999-07-30 2002-11-06 Abbott Gmbh & Co Kg 2-pyrazolin-5-ones
US7060822B1 (en) 1999-07-30 2006-06-13 Abbott Gmbh & Co. Kg 2-pyrazolin-5-ones
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
KR20070106690A (ko) 2004-12-27 2007-11-05 아스트라제네카 아베 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도
EP1905762A1 (en) 2005-05-30 2008-04-02 Genecare Research Institute Co., Ltd Pyrazolone derivative
WO2006129587A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体を含有する医薬組成物
BRPI0621959A2 (pt) 2006-08-18 2011-12-27 Syngenta Ltd usos de pelo menos um composto capaz de inibir 4-hidroxifenilpiruvato dioxigenase, e de um composto ou uma composiÇço, kit, e, composiÇço farmacÊutica
WO2009038411A2 (en) 2007-09-21 2009-03-26 Lg Life Sciences, Ltd. Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety
US10167263B2 (en) 2008-11-20 2019-01-01 Northwestern University Treatment of amyotrophic lateral sclerosis
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012074067A1 (ja) 2010-12-01 2012-06-07 日産化学工業株式会社 多発性骨髄腫の治療効果を有するピラゾール化合物
JP5946775B2 (ja) 2010-12-01 2016-07-06 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof

Also Published As

Publication number Publication date
IL247148A0 (en) 2016-09-29
NZ722345A (en) 2018-02-23
ZA201605222B (en) 2019-02-27
CN106029640B (zh) 2018-08-24
US9862708B2 (en) 2018-01-09
BR112016017781A2 (pt) 2017-08-08
JP2017505804A (ja) 2017-02-23
CA2937542A1 (en) 2015-08-20
SG11201606149YA (en) 2016-09-29
AU2015217450A1 (en) 2016-08-11
EP3105205A4 (en) 2017-08-02
AU2015217450A8 (en) 2016-09-08
EP3105205A1 (en) 2016-12-21
CN106029640A (zh) 2016-10-12
WO2015123133A1 (en) 2015-08-20
PE20161315A1 (es) 2016-12-25
US20180079745A1 (en) 2018-03-22
KR20160115996A (ko) 2016-10-06
US20170174666A1 (en) 2017-06-22
EA201691342A1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
MX2016010436A (es) Compuestos de pirazolona y usos de los mismos.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
PH12019500480A1 (en) Pyridine compound
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
EP3828186A3 (en) Pyrimidinones as factor xia inhibitors
SA518400493B1 (ar) مركبات كارفيلزوميب معالجة ببولي إيثيلين جليكول
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
PH12017500095A1 (en) Imidazopyridazine compounds
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
EA027986B9 (ru) Соединения триазолона и их применение
EA201891239A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
EA201692090A1 (ru) Полициклические активаторы herg
PH12017501214A1 (en) Cgrp antagonist peptides
PH12016501645A1 (en) Aminopyrazolone derivative
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
HK1231877A1 (en) Pyrazolone compounds and uses thereof
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.